Statutory PTE hinges on the “drug product” as the active ingredient, yet Federal Circuit guidance largely arises from small-molecule cases and leaves biologics-specific questions unresolved. Biologic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results